New Approval for Relapsing Forms of MS Tops SPT Week in Review – Pharmacy Times

Posted: Published on November 6th, 2019

This post was added by Alex Diaz-Granados

5. Cellular Respiration Significantly Increases in Patients with Primary Immunodeficiency DisordersMetabolic activity in the immune cells of patients with primary immunodeficiency was used as a biomarker due to cellular metabolism, which serves as a key regulator in immune cells. Read more.

4. Combo Therapy Shows High Response Rate in Unfit AML Patients With Certain BiomarkerAn ongoing phase 2 study is evaluating SY-1425 plus azacitadine in newly-diagnosed unfit patients with acute myeloid leukemia. Read more.

3. AI Could Improve Treatment for Crohn DiseaseA new computer method could help reveal the origins of Crohn disease and improve early diagnosis and accuracy. Read more.

2. FDA Report: Changes in Marketplace Needed to Mitigate Drug ShortagesThe FDA Drug Shortages Task Force addressed the root causes of drug shortages and proposed potential solutions. Read more.

1. FDA Approves Diroximel Fumarate for Relapsing Forms of Multiple SclerosisPatients in a phase 3 study reported better gastrointestinal tolerability with diroximel fumarate (Vumerity) compared with dimethyl fumarate (Tecfidera) in patients with relapsing forms of multiple sclerosis. Read more.

Excerpt from:
New Approval for Relapsing Forms of MS Tops SPT Week in Review - Pharmacy Times

Related Posts
This entry was posted in MS Treatment. Bookmark the permalink.

Comments are closed.